Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | High-risk myeloma and MUK Nine

Rakesh Popat • 15 May 2020
Multiple Myeloma

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, gives his perspective on the data submitted to BSH 2020 on the UKMRA OPTIMUM (MUK Nine) which looked at tailoring treatment for patients with high-risk newly diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Rakesh Popat

2:06
The optimal sequencing of CAR-T and other immunotherapies in multiple myeloma
Rakesh Popat • 16 Feb 2024
3:46
'Clinical case discussions' session rundown: HLH/MAS, aseptic meningitis, & CAR-NK cells in MM
Rakesh Popat • 16 Feb 2024
1:30
Selecting patients with myeloma for CAR-T: important clinical considerations
Rakesh Popat • 16 Feb 2024
1:14
The potential of CELMoDs for the treatment of R/R multiple myeloma
Rakesh Popat • 10 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals